How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Hospital-acquired infections (HAIs) Control Market
- By Product Type: Disinfectants and Sterilants, Hand Hygiene Products, Surveillance and Monitoring Systems, Antimicrobial Coatings, Diagnostic Testing Kits
- By Application: Surgical Site Infection Control, Catheter-Associated Urinary Tract Infection (CAUTI) Control, Ventilator-Associated Pneumonia (VAP) Control, Central Line-Associated Bloodstream Infection (CLABSI) Control, Clostridium difficile Infection Control
- By End User: Hospitals, Long-term Care Facilities, Ambulatory Surgical Centers, Diagnostic Laboratories, Outpatient Clinics
- By Technology: Automated Disinfection Systems, Rapid Diagnostic Technologies, Antimicrobial Surface Technologies, Infection Surveillance Software, UV-C Light Disinfection
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Disinfectants and Sterilants leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 286 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 17 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Hospital-acquired infections (HAIs) Control Market report
A complete, evidence-based study - 11 chapters and 120 sections covering market size, segmentation across 4 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →3M Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Ecolab Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →SteriLumen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Cantel Medical Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Getinge AB
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Advanced Sterilization Products (ASP) - Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →BD (Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Dickinson and Company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →STERIS plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Mölnlycke Health Care
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Cardinal Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Medline Industries Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Kimberly-Clark Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →ConvaTec Group PLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Nanosonics Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Diversey Holdings
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Disinfectants and Sterilants48.3
- Hand Hygiene Products7.7
- Surveillance and Monitoring Systems11.2
- Antimicrobial Coatings18.7
- Diagnostic Testing Kits14.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- 3M Company12.0
- Ecolab Inc.20.9
- SteriLumen10.0
- Cantel Medical Corporation5.2
- Getinge AB10.6
- Advanced Sterilization Products (ASP) - Johnson & Johnson13.2
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.5
- Europe24.1
- Asia Pacific21.0
- Latin America12.9
- Middle East and Africa10.5
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| 3M Company | 87 | 89 | 91 | 83 | 95 | 95 | 90 |
| Ecolab Inc. | 78 | 88 | 92 | 74 | 91 | 81 | 84 |
| SteriLumen | 83 | 71 | 73 | 82 | 86 | 86 | 80 |
| Cantel Medical Corporation | 78 | 61 | 59 | 74 | 67 | 69 | 68 |
| Getinge AB | 53 | 55 | 65 | 76 | 59 | 72 | 63 |
| Advanced Sterilization Products (ASP) - Johnson & Johnson | 63 | 59 | 64 | 55 | 71 | 47 | 60 |
| BD (Becton | 41 | 51 | 58 | 50 | 60 | 57 | 53 |
| Dickinson and Company) | 46 | 37 | 41 | 36 | 54 | 43 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- 3M Company
- Ecolab Inc.
- SteriLumen
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| 3M Company | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Ecolab Inc. | ◐ | ✓ | ✓ | ◐ | ✓ | ◐ |
| SteriLumen | ✓ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Cantel Medical Corporation | ✓ | ◐ | − | ◐ | ◐ | ✓ |
| Getinge AB | ◐ | − | ✓ | ◐ | ◐ | ◐ |
| Advanced Sterilization Products (ASP) - Johnson & Johnson | − | ◐ | − | ◐ | ◐ | ◐ |
| BD (Becton | − | − | ◐ | ◐ | ◐ | ◐ |
| Dickinson and Company) | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Challenger1
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Product Type in North America, then scale across Hospital-acquired infections (HAIs) Control Market — a $154M beachhead inside a $2.69B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Disinfectants and Sterilants
Best fit — highest urgency & budget in Product Type.
Hand Hygiene Products
Strong fit — clear ROI and a fast path to value.
Surveillance and Monitoring Systems
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Hospital-acquired infections (HAIs) Control Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Hospital-acquired infections (HAIs) Control Market is a high-growth opportunity — $1.61B by 2033, compounding at 11.4%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.4% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Hospital-acquired infections (HAIs) Control Market — a $5.19B market by 2033. Plan: grow share from 7.9% to 16.9%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.9% | 16.9% | On track |
| Revenue | $370M | $877M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 28.2% | 40.8% | At risk |
| Customer retention | 88.6% | 94.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $98M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Sales deck · value proposition
Win the Hospital-acquired infections (HAIs) Control Market conversation — a $8.68B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Hospital-acquired infections (HAIs) Control Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Hospital-acquired infections (HAIs) Control Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Hospital Acquired Infections Drugs Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportHospital-acquired Infection Diagnostics Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportHospital Acoustic Door Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportHospital Access Control Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportHospice Care Services Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportOptical Comparators Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportHoses for Medical Gases Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportFreezing Testers Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportHose Assemblies for Medical Gas Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportHorse Vaccines Market
Market size, share, segmentation and regional forecast.
$428M market · 2025 base year
View reportHorse Ultrasound Machine Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportHorse Chestnut Seed Extract Market
Market size, share, segmentation and regional forecast.
$844M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy